ESR1 and breast cancer: Notably, treatment with the cytostatic drug fulvestrant resulted in phenotypic responses exclusively in MCF-7 cells reflecting its function as a specific inhibitor of the estrogen receptor alpha signaling pathway, which is a specific trait of the MCF-7 breast cancer cell line50.